Dose optimisation of first-line tuberculosis drugs using therapeutic drug monitoring in saliva: feasible for rifampicin, not for isoniazid

Simone H J van den Elsen; Onno W Akkerman; Mireille Wessels; Erwin M Jongedijk; Samiksha Ghimire; Tjip S van der Werf; Mathieu S Bolhuis; Daan J Touw; Jan-Willem C Alffenaar

doi:10.1183/13993003.00803-2020

Dose optimisation of first-line tuberculosis drugs using therapeutic drug monitoring in saliva: feasible for rifampicin, not for isoniazid

Simone H J van den Elsen^*, Onno W Akkerman, Mireille Wessels, Erwin M Jongedijk, Samiksha Ghimire, Tjip S van der Werf, Mathieu S Bolhuis, Daan J Touw, Jan-Willem C Alffenaar

^*Corresponding author for this work

Research output: Contribution to journal › Comment/Letter to the editor › Academic › peer-review

10 Citations (Scopus)

120 Downloads (Pure)

Original language	English
Article number	2000803
Number of pages	4
Journal	European Respiratory Journal
Volume	56
Issue number	4
Early online date	2020
DOIs	https://doi.org/10.1183/13993003.00803-2020
Publication status	Published - 1-Oct-2020

Access to Document

10.1183/13993003.00803-2020

Dose optimisation of first-line tuberculosis drugsFinal author's version, 408 KB

Handle.net

Persistent link

Embargoed Document

Dose optimisation of first-line tuberculosis drugs using therapeutic drug monitoring in saliva_ feasible for rifampicin, not for isoniazid
Final publisher's version, 249 KB
Request copy

Cite this

van den Elsen, S. H. J., Akkerman, O. W., Wessels, M., Jongedijk, E. M., Ghimire, S., van der Werf, T. S., Bolhuis, M. S., Touw, D. J., & Alffenaar, J.-W. C. (2020). Dose optimisation of first-line tuberculosis drugs using therapeutic drug monitoring in saliva: feasible for rifampicin, not for isoniazid. European Respiratory Journal, 56(4), Article 2000803. https://doi.org/10.1183/13993003.00803-2020

@article{a4437c668d724b15ab4698e54287b6f7,

title = "Dose optimisation of first-line tuberculosis drugs using therapeutic drug monitoring in saliva: feasible for rifampicin, not for isoniazid",

author = "\{van den Elsen\}, \{Simone H J\} and Akkerman, \{Onno W\} and Mireille Wessels and Jongedijk, \{Erwin M\} and Samiksha Ghimire and \{van der Werf\}, \{Tjip S\} and Bolhuis, \{Mathieu S\} and Touw, \{Daan J\} and Alffenaar, \{Jan-Willem C\}",

year = "2020",

month = oct,

day = "1",

doi = "10.1183/13993003.00803-2020",

language = "English",

volume = "56",

journal = "European Respiratory Journal",

issn = "0903-1936",

publisher = "EUROPEAN RESPIRATORY SOC JOURNALS LTD",

number = "4",

}

van den Elsen, SHJ, Akkerman, OW , Wessels, M, Jongedijk, EM, Ghimire, S , van der Werf, TS , Bolhuis, MS , Touw, DJ & Alffenaar, J-WC 2020, 'Dose optimisation of first-line tuberculosis drugs using therapeutic drug monitoring in saliva: feasible for rifampicin, not for isoniazid', European Respiratory Journal, vol. 56, no. 4, 2000803. https://doi.org/10.1183/13993003.00803-2020

Dose optimisation of first-line tuberculosis drugs using therapeutic drug monitoring in saliva: feasible for rifampicin, not for isoniazid. / van den Elsen, Simone H J; Akkerman, Onno W ; Wessels, Mireille et al.
In: European Respiratory Journal, Vol. 56, No. 4, 2000803, 01.10.2020.

Research output: Contribution to journal › Comment/Letter to the editor › Academic › peer-review

TY - JOUR

T1 - Dose optimisation of first-line tuberculosis drugs using therapeutic drug monitoring in saliva

T2 - feasible for rifampicin, not for isoniazid

AU - van den Elsen, Simone H J

AU - Akkerman, Onno W

AU - Wessels, Mireille

AU - Jongedijk, Erwin M

AU - Ghimire, Samiksha

AU - van der Werf, Tjip S

AU - Bolhuis, Mathieu S

AU - Touw, Daan J

AU - Alffenaar, Jan-Willem C

PY - 2020/10/1

Y1 - 2020/10/1

U2 - 10.1183/13993003.00803-2020

DO - 10.1183/13993003.00803-2020

M3 - Comment/Letter to the editor

C2 - 32398308

SN - 0903-1936

VL - 56

JO - European Respiratory Journal

JF - European Respiratory Journal

IS - 4

M1 - 2000803

ER -